Navigation Links
Mylan Launches Generic Version of Plavix® Tablets
Date:5/17/2012

PITTSBURGH, May 17, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clopidogrel Tablets USP, 75 mg and 300 mg. The company was the first to have filed a substantially complete ANDA containing a Paragraph IV certification to the FDA for Clopidogrel Tablets, 300 mg, and was awarded 180 days of marketing exclusivity for this strength. This product is the generic version of Sanofi-Aventis' Plavix® and is indicated for acute coronary syndrome and for patients with a recent history of myocardial infarction, stroke or established peripheral arterial disease.[1]

Mylan Pharmaceuticals will provide customers with the 75 mg strength of this product in bottle form, and Mylan Institutional, which serves the institutional pharmaceutical market, will supply the 300 mg strength exclusively in unit dose packs of 30. This business also will supply Clopidogrel Tablets, 75 mg, in unit dose packs of 100. Mylan is shipping all product presentations immediately.

Plavix Tablets, 75 mg and 300 mg, had U.S. sales of approximately $6.7 billion for the 12 months ending March 31, 2012, according to IMS Health.

Currently, Mylan has 173 ANDAs pending FDA approval representing $98.2 billion in annual sales, according to IMS Health. Thirty-nine of these pending ANDAs are potential first-to-file opportunities, representing $25.5 billion in annual brand sales, for the 12 months ending Dec. 31, 2011, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do wha
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Mylan Launches Generic Lipitor® in Five European Countries
2. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
3. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva
4. Mylan Launches Generic Version of Zyprexa® Tablets
5. Mylan Launches First Generic Version of Lescol® Capsules
6. Mylan Schedules First Quarter 2012 Financial Results Conference Call and Live Webcast
7. Mylan One of First to Launch Generic Version of Boniva®
8. Mylan Canada Receives Health Canada Approval for Generic Version of Crestor®
9. Mylan Continues to Pursue Damages and Injunction Against Sunovions Brovana® in Ongoing Litigation
10. Mylan Pharmaceuticals President Tony Mauro Elected Chairman of GPhA
11. Mylan Secures an Additional $300 Million of Committed Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... to present a corporate overview and update at the Piper ... 2, 2014, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific ... New York . A live audio webcast ... section of Arena,s website at www.arenapharm.com . A replay ...
(Date:11/24/2014)... 24, 2014 Luoxis Diagnostics, Inc., a ... today announced the presentation of three clinical and ... a broadly applicable and robust research tool capable ... in response to injury, illness, or stress.  In ... with Luoxis, academic and pharmaceutical research partners, RedoxSYS ...
(Date:11/24/2014)... The Female Health Company (NASDAQ-CM: FHCO), today ... to discuss its operating results for the fourth quarter ... December 2, 2014 at 11:00 a.m. Eastern Standard Time ... earlier the same day. Shareholders and other ... dialing 1-877-374-8416 (international participants dial 1-412-317-6716) and asking to ...
Breaking Medicine Technology:Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5The Female Health Company To Report FY2014 Operating Results on Tuesday, December 2, 2014 2
... , MAPLE GROVE, Minn., Dec. 3 Upsher-Smith ... plan for central nervous system (CNS) diseases with USL255 (extended ... epilepsy. USL255 is being developed with Upsher-Smith,s proprietary formulation technology ... 2010 for the adjunctive treatment of epilepsy patients with partial ...
... , HARRISBURG, Pa., Dec. 3 ... processing company build a new cold storage facility and ... at least 20 jobs, Governor Edward G. Rendell announced ... more than $2.9 million for three projects. The investments, ...
Cached Medicine Technology:Upsher-Smith Announces Milestone in Development of CNS Strategy 2Governor Rendell: New State Investments Bear Fruit in Adams County; Help Pharmaceutical Company Expand in Philadelphia 2
(Date:11/24/2014)... Mental health issues affect tens of ... families, ruin careers, and generally destroy lives. , ... suffer,” says Hardy Nutritionals® founder David ... specialized nutritional treatments can reverse these disorders naturally.” ... Matter”, the premiere episode of O2 Media’s new ...
(Date:11/24/2014)... Dr. Michael Kettel , a leading fertility ... NBC to discuss egg freezing as a viable and increasingly ... the news recently, with new company benefits at Facebook and ... , “[The companies] see it as a way to take ... path.” Says Dr. Kettel. , Up until a few weeks ...
(Date:11/23/2014)... TX (PRWEB) November 23, 2014 ... Devices Market 2006 to 2020 - Asia-Pacific” provides ... energy devices market segments: minimally invasive body contouring ... devices. The analysis includes market size data by ... for the following countries: China, Japan, South Korea, ...
(Date:11/23/2014)... -- The holidays can be a challenge for families ... major meltdowns, an expert says. "Holidays with family ... when you have children with special needs, some care ... at University of the Sciences in Philadelphia, said in ... your hosts or visitors know what special requirements are ...
(Date:11/23/2014)... November 23, 2014 More than two ... in a federal litigation involving Byetta lawsuits ( http://www.byettalawsuit2013.com/ ... Bernstein Liebhard LLP reports. , A Case List ... a class of Type 2 diabetes medications referred to ... U.S. District Court, Southern District of California, where a ...
Breaking Medicine News(10 mins):Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 2Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 3Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4Health News:Holidays Can Be Sensory Overload for Kids With Autism 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4
... East Anglia have found that gold nanoparticles are very ... reveal the presence of poisons far faster than existing ... lab. This they hope would help in aiding investigations ... David Russell use of gold nanoparticles that are only ...
... being hailed as a milestone, researchers at the Wake Forest ... in laboratory conditions and what’s more// have implanted these bladders ... led by Dr. Anthony Atala has published their experimental study ... the seven children in the study were suffering from a ...
... a preliminary investigation it has been found that if there ... liver disease late on.// ,This case control ... the above mentioned result. Intrahepatic cholestasis of pregnancy (ICP) is ... the liver. ,The study is published in the ...
... and you are on a dieting course, there might be ... Nutrition scientists from// Arizona State University report that the amount ... with the lower body fat. ,If there is far ... cause increased body fat and waist measurements. Nutrition researchers from ...
... 155 million population carries the deadly hepatitis virus, a ... ,"Hepatitis B and C is a time bomb waiting ... control it," said the president of the Pakistan Medical ... report. ,The association represents medical practitioners and ...
... A new study has revealed that skateboarders have better ... compared to their more sedentary peers. // ... April issue of Pediatrics. It is authored by Melissa ... with co-author Dr. Penny Gordon-Larsen, an assistant professor of ...
Cached Medicine News:Health News:Gold Nanoparticles Are Good Detectors Biological Toxins 2Health News:Intrahepatic cholestasis during pregnancy predisposes to later liver disease 2Health News:Vital Facts of Short Term Diets - Catch The Vitamin Behind An Ample Waist! 2
... Sonys new DFW-SX910 digital camera is equipped ... with square pixels and offers excellent sensitivity ... This camera delivers uncompressed, high-resolution, ... asynchronous electronic shutter function with an exposure ...
... the latest in imaging technology with the 12.5 ... high resolution, high sensitivity, and high-speed data transfer ... fluorescence. CCD - 2/3" Single ... Depth - 36-bit Exposure Range ...
4 megapixel zoom digicam with a 4x optical zoom, Effective pixels:4.0 million CCD:1/1.8-in. type (4.13 million total pixels), Max Image size:2272 (2,272 x 1,704 pixels), Lens:4x Zoom-Nikkor; f = 7.85...
... stand-alone digital camera with networking capability for ... remote locations. Image acquisition and camera manipulation ... independently or attaches directly to a LAN/WAN. ... capture and transfer images. Sharing images in ...
Medicine Products: